Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

M.D., Merck’s head of general medicine, global clinical development, said in an interview with Fierce Pharma. “There has not been a PH study that used an endpoint based on death ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO ...

Merck on Tuesday said it will make an upfront payment of $200 million to Hengrui Pharma to license HRS-5346, which is currently in a Phase 2 study in China for the reduction of lipoprotein(a), or ...